Elvitegravir belongs to the class of antiretroviral drugs known as integrase inhibitors. The drug works against HIV's integrase protein, blocking its ability to integrate its genetic code into human cells.
As an individual drug (Vitekta), elvitegravir was given marketing approval in Europe in November 2013. However, marketing authorisation was removed at the request of the drug's maker, Gilead Sciences, in late 2016. Gilead decided to stop marketing the drug for commercial reasons.
Elvitegravir is still available as part of the combination products Stribild (combined with tenofovir disoproxil, emtricitabine and cobicistat) and Genvoya (combined with tenofovir alafenamide, emtricitabine and cobicistat).